Skip to main content

Table 1 Summary of baseline patient demographics and characteristics

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Baseline demographics and disease characteristicsa Episodic migraine
N = 1338
Chronic migraine
N = 836
  Placebo
(n = 894)
Galcanezumab 120 mg
(n = 444)
Placebo
(n = 558)
Galcanezumab 120 mg
(n = 278)
Age (years), mean (SD) 41.9 (11.4) 40.9 (11.5) 41.6 (12.1) 39.7 (11.9)
Gender (female), n (%) 755 (84.5) 378 (85.1) 483 (86.6) 237 (85.3)
Race (white), n (%) 681 (76.2) 335 (75.5) 432 (77.4) 223 (80.2)
Ethnicity (not Hispanic or Latino), n (%) 677 (79.4) 342 (80.1) 401 (76.7) 195 (74.7)
Region, North America, n (%) 657 (73.5) 325 (73.2) 321 (57.5) 161 (57.9)
Duration of migraine disease (years), mean (SD) 20.5 (12.5) 20.5 (12.3) 21.9 (12.9) 20.4 (12.7)
Migraine headache days/month, mean (SD) 9.1 (3.0) 9.1 (3.0) 19.6 (4.6) 19.4 (4.3)
MIDAS total score, mean (SD) 33.1 (29.3) 31.9 (28.0) 68.7 (57.4) 62.5 (49.5)
MSQ total score, mean (SD) 58.8 (16.4) 58.2 (16.1) 44.4 (17.9) 45.2 (18.2)
Total monthly pain severity-weighted duration in hours, mean (SD) 123.9 (92.2) 122.4 (90.5) 321.2 (231.3) 324.5 (212.0)
  1. Note: Daily severity-weighted duration was calculated as duration (in hours) x pain severity (none = 0, mild = 1, moderate = 2, severe = 3)
  2. Abbreviations: MIDAS Migraine Disability Assessment, MSQ Migraine-Specific Quality of Life Questionnaire version 2.1, SD standard deviation
  3. aIncludes pooled data from two 6-month episodic migraine studies and one 3-month chronic migraine study